Matthew Zola 1/8/26 Matthew Zola 1/8/26 EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology Read More Jamison Wright 4/28/25 Jamison Wright 4/28/25 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Read More Christine Mackenzie 11/4/24 Christine Mackenzie 11/4/24 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Read More Christine Mackenzie 4/8/24 Christine Mackenzie 4/8/24 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Read More Christine Mackenzie 7/20/23 Christine Mackenzie 7/20/23 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Read More Jamison Wright 3/22/23 Jamison Wright 3/22/23 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Read More
Matthew Zola 1/8/26 Matthew Zola 1/8/26 EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology Read More
Jamison Wright 4/28/25 Jamison Wright 4/28/25 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Read More
Christine Mackenzie 11/4/24 Christine Mackenzie 11/4/24 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Read More
Christine Mackenzie 4/8/24 Christine Mackenzie 4/8/24 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Read More
Christine Mackenzie 7/20/23 Christine Mackenzie 7/20/23 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Read More
Jamison Wright 3/22/23 Jamison Wright 3/22/23 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Read More
